Dr. Neil Fleshner, MD
Claim this profileUniversity Health Network
Area of expertise
Prostate Cancer
Neil Fleshner, MD has run 6 trials for Prostate Cancer. Some of their research focus areas include:
Ductal Carcinoma In Situ
Neil Fleshner, MD has run 1 trial for Ductal Carcinoma In Situ.
Affiliated Hospitals
Princess Margaret Cancer Centre
University Health Network
Clinical Trials Neil Fleshner, MD is currently running
Genomic Biomarker-Selected Therapy
for Prostate Cancer
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response. Each participant will be treated with 8 weeks of a luteinizing hormone-releasing hormone agonist (LHRHa) plus apalutamide (APA) while genome sequence characterization is being done. Participants with biopsy specimens deemed unevaluable for genomic testing will remain on LHRHa plus APA for an additional 16 weeks. Participants with evaluable tissue will be assigned to one of the open-label sub-studies on the basis of genomic profiling results. Within each group, they will be randomized to a specific treatment arm either LHRHa plus APA alone or adding abiraterone acetate and prednisone, docetaxel or niraparib. The study will evaluate the response rate and outcomes after radical prostatectomy in each arm of the trial.
Recruiting
1 award
Phase 2
10 criteria
Photodynamic Therapy
for Prostate Cancer
This trial tests a new treatment using lasers and a special drug for men whose prostate cancer has returned. The laser activates the drug to destroy cancer cells.
Recruiting
2 awards
Phase 1 & 2
More about Neil Fleshner, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Neil Fleshner, MD has experience with
- Metformin
- Darolutamide
- Degarelix
- Radiation Therapy
- Abiraterone Acetate 250mg
- Apalutamide
Breakdown of trials Neil Fleshner, MD has run
Prostate Cancer
Ductal Carcinoma In Situ
Metabolic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Neil Fleshner, MD specialize in?
Neil Fleshner, MD focuses on Prostate Cancer and Ductal Carcinoma In Situ. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are metastatic.
Is Neil Fleshner, MD currently recruiting for clinical trials?
Yes, Neil Fleshner, MD is currently recruiting for 2 clinical trials in Toronto Ontario. If you're interested in participating, you should apply.
Are there any treatments that Neil Fleshner, MD has studied deeply?
Yes, Neil Fleshner, MD has studied treatments such as Metformin, Darolutamide, Degarelix.
What is the best way to schedule an appointment with Neil Fleshner, MD?
Apply for one of the trials that Neil Fleshner, MD is conducting.
What is the office address of Neil Fleshner, MD?
The office of Neil Fleshner, MD is located at: University Health Network, Toronto, Ontario M5G 2C4 Canada. This is the address for their practice at the University Health Network.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.